1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. New Jersey >
  6. Eisai Acquires AkaRx

M&A Deal Summary

Eisai Acquires AkaRx

On January 6, 2010, Eisai acquired life science company AkaRx for 255M USD

Acquisition Highlights
  • This is Eisai’s 1st transaction in the Life Science sector.
  • This is Eisai’s largest (disclosed) transaction.
  • This is Eisai’s 1st transaction in the United States.
  • This is Eisai’s 1st transaction in New Jersey.
Investment Fate
  • AkaRx was divested to a consortium of buyers in 2016.

M&A Deal Summary
Date 2010-01-06
Target AkaRx
Sector Life Science
Buyer(s) Eisai
Deal Type Add-on Acquisition
Deal Value 255M USD

Target

AkaRx

Paramus, New Jersey, United States
AkaRx is a developer of the Avatrombopag drug. Avatrombopag is an investigational oral thrombopoietin receptor agonist. AkaRx was founded in 2004 and is based in Paramus, New Jersey.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Eisai

Woodcliff Lake, New Jersey, United States
Category Company
Founded 1995
Sector Life Science
DESCRIPTION

Eisai, Inc. is a pharmaceutical company focuses on neurology, gastrointestinal disorders and oncology/critical care.

DEAL STATS #
Overall 1 of 2
Sector: Life Science M&A 1 of 2
Type: Add-on Acquisition M&A Deals 1 of 1
State: New Jersey M&A 1 of 1
Country: United States M&A 1 of 2
Year: 2010 M&A 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-30 AkaRx

Paramus, New Jersey, United States

AkaRx is a developer of the Avatrombopag drug. Avatrombopag is an investigational oral thrombopoietin receptor agonist. AkaRx was founded in 2004 and is based in Paramus, New Jersey.

Sell -
Mergr

Solution for

Product

Company

Legal